You may be right I don’t know. My thinking in my is that the merger was mutually beneficial in that TPIV brought some big investors and public company experience while MRKR science was a good addition to their oncology portfolio and probably the big future money maker. I haven’t seen or heard from Knutson I’m some time and that can’t bode well for TPIV vaccines.
News 
Market Data 
Discover 
